AMPEL is a precision medicine company raising funds for 2022 commercialization of a first-in-class CLIA-certified gene-based LDT blood test for Lupus patients that will assess disease status, predict flares and match patients with best drug options. Filed patents protect AMPEL’s genomic platform, bioinformatic tools and machine learning algorithms that were developed in-house and are wholly owned by the company. AMPEL’s exclusive curated database of >10,000 Lupus patients is the world’s largest and fuels machine learning predictions. AMPEL validated it’s approach with 5+Pharma customers by accelerating trial success by identifying patients for trials that express the target/pathway of the drug being tested. 

Lupus patients (US, 1.5M) are not treated precisely because there is no objective method to evaluate disease activity and predict responsiveness to medication. Based on the cost of reimbursed genomic tests in oncology, AMPEL’s estimated market for LuGENE® >$5B a year with revenue projections of $9.75M in 2022, $56M in 2023 and $120M in 2024. Potential competitors in the Lupus biomarker space have little to no genomic capability or are focused narrowly on a few genes and have no machine learning capability. AMPEL’s proprietary platform provides full-genome coverage for LuGENE® and the capacity to expand reporting of results into new disease indications without developing a new test. 

AMPEL is revenue-positive (2016-present) and has raised significant funds ($8.4M non-dilutive funding). In addition to bringing LuGENE® to market in 2022, AMPEL validated in COVID19 and oncology with patents filed and is in discussions with potential strategic partners in these disease areas.